Cell Genesys Sells Lentiviral Delivery Technology to Lentigen
Cell Genesys announced last month that it has sold its lentiviral gene-delivery technology to GBP Capital, the majority shareholder of gene delivery firm Lentigen, for $12 million.
The deal covers all intellectual property related to the lentiviral vector technology, as well as existing licensing arrangements. Cell Genesys will retain rights to the technology for research and development purposes.
Management of technology and IP, the companies said, has been assigned to Lentigen by GBP.
Additional terms of the arrangement were not disclosed.
Promega to Open Office in Sweden This Month
Promega said late last month that it will open an office in Stockholm in January to offer its products and services directly to the Swedish research community.
The company, based in Madison, Wis., previously offered its products in Sweden through a distribution deal with SDS BioSciences.
The company has hired Patrick Van de Velde as general manager of the office.
In a statement, Promega CEO William Linton said that Sweden has the fourth-largest biotech industry in Europe with 48,000 full-time employees in R&D and the highest R&D expenditure per capita.